Sanam Loghavi: Menin inhibitors in AML—exciting development and combination therapies

Sanam Loghavi posted the following on X:

“Menin inhibitors are the most exciting class of drugs in development for AML. A very nice summary of menin-i development timeline & outcome data with menin-i combination therapies by Ghayas Issa, Joshua Zeidner, and Eunic Wang. Chaired by Daver Leukemia at iWAL24.”

Source: Sanam Loghavi/X

Sanam Loghavi is an Associate Professor of Pathology and Laboratory Medicine at the Department of Hematopathology at MD Anderson Cancer Center.  She is the Medical Director of the ECOG/ACRIN Leukemia Bank at the Central Biorepository and Pathology Facility at MD Anderson. She has authored around 200 peer-reviewed publications focused on hematologic neoplasms and is a co-investigator on several national and internationally-run clinical trials for hematologic malignancies.

She serves on various committees including the HPATH Committee of the College of American Pathologists and the Education and Outreach Committees for International Clinical Cytometry Society.